All NewsFDA BriefsOncology IconsSpecial ReportsVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision Medicine
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CME/CE
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
eNewsletterPrint Subscription
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2-Positive Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CME/CE
Advertisement

Nancy Lin, MD

home / authors / nancy-lin,-md

Articles

Advertisement

Survival Advantage Observed in HER2+Breast Cancer With Brain Metastasis

Survival Advantage Observed in HER2+Breast Cancer With Brain Metastasis

October 1st 2020

Nancy U. Lin, MD, discusses the results from a substudy of HER2CLIMB looking at tucatinib plus trastuzumab and capecitabine in patients with HER2-positive breast cancer and brain metastases.


HER2CLIMB Regimen Can Be Used Earlier in HER2+ Metastatic Breast Cancer

HER2CLIMB Regimen Can Be Used Earlier in HER2+ Metastatic Breast Cancer

September 16th 2020

Nancy U. Lin, MD, discusses how she would use the HER2CLIMB regimen of tucatinib plus trastuzumab and capecitabine now that it has been approved for treatment of patients with HER2-positive metastatic breast cancer.


HER2CLIMB Study Shows Efficacy in HER2 Breast Cancer With Brain Metastases

HER2CLIMB Study Shows Efficacy in HER2 Breast Cancer With Brain Metastases

July 1st 2020

Nancy U. Lin, MD, discusses the latest findings from the HER2CLIMB study of either tucatinib or placebo, added to trastuzumab and capecitabine, for patients with previously treated HER2-positive metastatic breast cancer who have brain metastases.


Systemic Therapies Shown to be Effective in HER2-Positive Breast Cancer

Systemic Therapies Shown to be Effective in HER2-Positive Breast Cancer

April 20th 2020

Nancy Lin, MD, discusses options for patients with human epidermal growth factor receptor 2-positive breast cancer who also present with brain metastases.

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.